Alpha-GPC, a choline-rich supplement, enhances brain health by increasing acetylcholine, with potential applications in ...

In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...

Elon Musk says he will abandon his $97.4 billion offer to buy the nonprofit behind OpenAI if the ChatGPT maker drops its plan to convert into a for-profit company. “If OpenAI, Inc.’s Board is ...

There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Gov. Josh Shapiro on Tuesday delivered a $51.5 billion budget proposal for the 2025-2026 fiscal year that he touted as a plan ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

Recent studies have shed light on these medications’ benefits and potential risks. Ozempic’s common side effects include nausea, diarrhea, constipation, and acid reflux, which are generally mild ...

To that end, we conducted a series of human and animal studies which produced ... technology platform within, and outside of, GLP-1…Our R&D plans for 2025 will remain concentrated on GLP-1 ...

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs.